Experts from all over Europe working towards
a wider use of In Silico Trials

Lowering the barriers
to a universal adoption
of In Silico Trials

The In Silico World project aims at accelerating the uptake of modelling and simulation technologies used for the development and regulatory assessment of medicines and medical devices, by lowering seven identified barriers: development, validation, accreditation, optimisation, exploitation, information, and training.

Our mission and vision

A wider adoption
of In SilicoTrials
in the biomedical
industry

Our mission is lowering the barriers to a universal adoption of In Silico Trials

 

Our vision is a future
where medical products, thanks to the use of modelling and simulation, are developed much faster and with
the highest possible safety standards

Researchers

Discover more
Here you can access all the resources that help accelerating the adoption of the In
Silico Trials solutions you developed:
connect with your community of peers

Industry

Collaborate
Learn how adopting of in silico trials for
the assessment of new medical products can offer your company a substantial competitive advantage

Clinicians

Discover more
Discover what is in silico medicine, its strengths and weaknesses and how it can be used in computer simulations for patient-specific clinical decision support, and to assess new medical
products

Patients and Public

Discover more
Learn how In Silico Trials can transform healthcare, by providing better, safer and
cheaper medical products

Twitter

Find us
on Twitter

Follow
Would you like to know more about In Silico World?
Do you have any questions for us?

Want to get in touch?

Connect to the
In Silico World
Community

Join the community
Consortium

Meet the people

Discover more
The In Silico World consortium sees the participation of world-class leaders in technological research, clinical research, and industrial innovation in the field of In Silico Trials from six European countries.
We count on a total of more than 100 professionals from 17 partner institutions including universities, companies,
research hospitals, an international research centre, a non-governmental organisation and a standardisation body

Alma Mater Studiorum – Università di Bologna (UNIBO)

Read more

UNIBO is the project Coordinator and WP1 leader.

Most of the activities assigned to partner UNIBO in the ISW project will be responsibility of the In Silico Medicine Group led by Prof Marco Viceconti, based at the Department of Industrial Engineering.

 

Principal Investigator: Prof. Marco Viceconti

Insilico World - Consortium - UNIBO

Universiteit van Amsterdam (UvA)

Read more

The Computational Science Lab of the faculty of Science of the University of Amsterdam aims to describe and understand how complex systems in nature and society process information.

UvA will participate in the project providing its competences in advanced modelling, regulatory aspects, and computing aspects.

 

Principal Investigator: Prof. Alfons Hoekstra

Insilico World - Consortium - UvA

Technische Universiteit Eindhoven (TU/e)

Read more

Eindhoven University of Technology (TU/e) is a research university specializing in engineering science & technology.

TUE will lead and mainly be involved in WP3 – curation of different validation data collections and WP9 – legal provisions and relevant ethical considerations, for the aspects of data management.

 

Principal Investigator: Prof. Frans van de Vosse

Insilico World - Consortium - Tue

Università degli Studi di Catania (UNICT)

Read more

In the Department of Drug and Health Sciences, the Computational Systems Biomedicine Research Group – COMBINE (https://www.combine-group.org) drives the research in applying computational methodologies to the field of biomedicine.

UNICT is the scientific Coordinator and WP4 leader.

 

Principal Investigator: Prof. Francesco Pappalardo

Insilico World - Consortium - UNICT